Published in Vaccine Weekly, September 20th, 2000
The grant was awarded to Aquila under Phase I of the Small Business Innovation Research (SBIR) Program of the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) branch of NIH.
"The SBIR grant for the development of a novel vaccine for S. aureus further validates our CD1 technology and the opportunities it opens for new...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly